# Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Retrospective Analysis of Loco-Regional Recurrences and Survival Rates Over a Consecutive 10-Year Period

## TL;DR

This study analyzed 10 years of data to identify risk factors for recurrence and survival rates in head and neck skin cancer patients.

## Contribution

The study identifies multiple risk factors for recurrence in cutaneous squamous cell carcinoma through a large retrospective cohort analysis.

## Key findings

- 29 patients (3%) developed loco-regional recurrences with a median time to recurrence of 25 months.
- Factors like depth of invasion, tumor size, and immunosuppression strongly predict recurrence.
- Recurrence-free survival rates were 95.6% at one year and 59.9% at five years.

## Abstract

Introduction: Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers worldwide. Due to the ever-increasing sun exposure and life expectancy, cSCCs are increasing worldwide. The aim of our study was to identify specific risk factors leading to local and regional recurrences, determine patients’ survival rates, and identify best practices for the management of cSCC.

Methodology: This study retrospectively analyzed 1197 head and neck cSCCs in 945 patients who consecutively presented to the clinics from January 2007 to December 2016. Patients were followed up for a minimum of 18 months.

Results: A total of 29 patients (3%) developed loco-regional recurrences (26 local, one regional, and two both local and regional) with a median time to recurrence of 25 (range, 1-81) months. The mean follow-up was 32 (range, 5-90) months. Treatment modality (p=0.027), depth of invasion (p<0.001), diameter > 20 mm (p<0.001), gender (p=0.022), histological differentiation (p<0.001), site of the lesion (p<0.001), perineural and intravascular invasion (p<0.001), positive lymphadenopathy (p=0.021), immunosuppression (p<0.001), and history of treatment (p=0.008) proved to be strong predictors for loco-regional recurrences. At one and five years after diagnosis, 95.6% and 59.9% of all patients were recurrence-free, respectively. The median survival time from recurrence was 2.6 years.

Conclusion: Our study identifies prognostic indicators for reoccurrence by analyzing data from a large continuous cohort in the management of cSCCs.